Term
|
Definition
| cholinergic agonist (both muscarinic and nicotinic) |
|
|
Term
|
Definition
| cholinergic agonist (muscarinic only) |
|
|
Term
|
Definition
| acetylcholine-esterase inhibitor; helps drainage of eye with high IOP |
|
|
Term
|
Definition
| cholinergic antagonist (muscarinic only) |
|
|
Term
|
Definition
| cholinergic antagonist (nicotinic only) |
|
|
Term
|
Definition
| cholinergic antagonist (nicotinic only) |
|
|
Term
|
Definition
| inhibits synthesis of acetylcholine |
|
|
Term
|
Definition
| inhibits release of acetylcholine from presynaptic neuron |
|
|
Term
|
Definition
| noradrenergic agonist (alpha-1 only) |
|
|
Term
|
Definition
| noradrenergic agonist (beta-1 only) |
|
|
Term
|
Definition
| blocks noradrenergic Reuptake I, increasing NE concentration in synapse |
|
|
Term
|
Definition
| reverses noradrenergic Reuptake I, increasing NE release |
|
|
Term
|
Definition
| non-selective noradrenergic antagonist (alpha-1 only); reversibly bound |
|
|
Term
|
Definition
| non-selective noradrenergic antagonist (beta-1 only); reversibly bound |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibits noradrenergic synthesis by preventing the action of tyrosine hydroxylase (rate-limiting step) |
|
|
Term
|
Definition
| prevents vesicles from storing NE |
|
|
Term
|
Definition
| false noradrenergic transmitter, acts as α2 agonist; has different properties than NE in the CNS, same properties as NE in the periphery |
|
|
Term
|
Definition
| prototype INDIRECT-acting drug (release or block reuptake of released NE) |
|
|
Term
|
Definition
| prototype DIRECT-acting drug (combine directly with the receptor to produce a response; also removed from terminal by Uptake 1); α1, α2, β1, β2 |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: α1, α2, β1 |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: α1; nasal decongestant, maintains BP during anesthesia, produces mydriasis |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: β1, β2; reduces diastolic BP, stimulates the heart, bronchodilation |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: less β1, more β2; treat acute asthma, fast-acting, short duration |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: less α1, more β1, less β2 |
|
|
Term
|
Definition
| Direct-acting sympathomimetic: less α1, more α2 |
|
|
Term
|
Definition
| MAO (monoamine oxidase) inhibitor |
|
|
Term
|
Definition
| COMT (catechol-O-methyl transferase) inhibitor |
|
|
Term
|
Definition
| β2 agonist; treat acute asthma, fast-acting, short duration |
|
|
Term
|
Definition
| β2 agonist; treat chronic asthma, long duration, must be given with corticosteroid |
|
|
Term
|
Definition
| β2 agonist; treat chronic asthma, long duration, must be given with corticosteroid |
|
|
Term
|
Definition
| β2 agonist; relaxes uterine smooth muscle during 3rd trimester |
|
|
Term
|
Definition
| β1 agonist; increases heart contraction, to treat low cardiac output, short-acting |
|
|
Term
| dobutamine (analog of dopamine) |
|
Definition
| β1 agonist; increases heart contraction, to treat low cardiac output, very short duration |
|
|
Term
|
Definition
| indirect-acting sympathomimetic |
|
|
Term
|
Definition
| indirect agonist at α1, β1; direct agonist at β2; less potent and longer acting than epinephrine |
|
|
Term
|
Definition
| indirect agonist at α1, β1 |
|
|
Term
|
Definition
| non-selective α adrenergic antagonist; irreversibly bound |
|
|
Term
|
Definition
|
|
Term
|
Definition
| selective α1 antagonist; longer-acting than prazosin |
|
|
Term
|
Definition
| selective α1A antagonist; used for treating BPH |
|
|
Term
|
Definition
| non-selective β adrenergic antagonist; long-acting |
|
|
Term
|
Definition
| non-selective β adrenergic antagonist; oral and topical application for glaucoma |
|
|
Term
|
Definition
| non-selective β adrenergic antagonist with modest β1 agonist effects (less slowing of the heart and changes in plasma triglycerides) |
|
|
Term
|
Definition
| non-selective β adrenergic antagonist with α1 antagonist properties; used mostly in emergencies |
|
|
Term
|
Definition
| non-selective β adrenergic antagonist with α1 antagonist properties; longer half-life than labetalol |
|
|
Term
|
Definition
| selective β1 adrenergic antagonist; short-acting |
|
|
Term
|
Definition
| selective β1 adrenergic antagonist; longer half-life than metoprolol; most common |
|
|
Term
|
Definition
| selective β1 adrenergic antagonist; extremely short half-life; used for emergencies |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibits enzyme tyrosine hydroxylase (the rate-limiting step in catecholamine, NE & DA, synthesis) |
|
|
Term
|
Definition
| inhibits enzyme decarboxylase in periphery, reducing the effects of dopamine in the periphery; usually given with L-DOPA; allows more to pass BBB to replace DA in Parkinson's |
|
|
Term
|
Definition
| inhibits peripheral COMT (inactivates L-DOPA); increases amount of circulating L-DOPA |
|
|
Term
|
Definition
| inhibits enzyme MOA; used to treat depression; be cautious of use with tyramine |
|
|
Term
|
Definition
| direct muscarinic agonist; used to open the drainage angle in the eye, decreasing IOP |
|
|
Term
|
Definition
| AChE inhibitor; used to reduce high IOP |
|
|
Term
|
Definition
| inhibits enzyme phosphodiesterase type 5; extends vasodilation in parasympathetically innervated vascular smooth muscle (penis) |
|
|
